- Annual Meeting
- Practice Resources
- Study Groups
- ISOO – Oral Oncology
MASCC Neutropenia, Infection & Myelosuppression Study Group
2017 Annual Meeting Workshop, June 22, Washington, DC
This workshop will be offered jointly by the following MASCC Study Groups: Antiemetics; Neutropenia, Infection, and Myelosuppression; Oral Care; Psychosocial.
Identifying Patients at Low Risk for FN Complications: Development and Validation of the MASCC Risk Index Score
Calculate by QxMD - (Free) Calculate the MASCC Febrile Neutropenia score in addition to included tools which are useful in clinical practice and serve to impact diagnosis, treatment or determining prognosis.
MASCC-Endorsed Practice Guidelines
Georgala A, Klastersky JA. Prophylaxis of febrile neutropenia in adults receiving chemotherapy needs to be adapted to the risk. Expert Rev Hematol. 2015 Feb;8(1):115-21.
Klastersky J, Georgala A. Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria. Crit Rev Oncol Hematol. 2014 Dec;92(3):268-78.
Klastersky JA. Supportive care is a constant state of changing: we need to adjust for it. Curr Opin Oncol. 2014 Jul;26(4):371.
Klastersky JA. Adverse events of targeted therapies. Curr Opin Oncol. 2014 Jul;26(4):395-402.
Klastersky JA. Supportive care in cancer patients: a unifying concept. Curr Opin Oncol. 2013 Jul;25(4):341.
Klastersky J, Raftopoulos H, Rapoport B. The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. Support Care Cancer. 2013 Jun;21(6):1793-5.
Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013 May;21(5):1487-95.
Aapro MS, Bholius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al.; for the European Organisation for Research and Treatment of Cancer. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 Jan;47(1):8-32.
Rapoport BL. Management of the cancer patient with infection and neutropenia. Semin Oncol. 2011 Jun;38(3):424-30.
Please contact the Study Group Chairs above with your questions.